Cargando…

Immune Responses to Plasma-Derived Versus Recombinant FVIII Products

The most severe side effect of hemophilia treatment is the inhibitor development occurring in 30% of patients, during the earliest stages of treatment with factor (F)VIII concentrates. These catastrophic immune responses rapidly inactivate the infused FVIII, rendering the treatment ineffective. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peyvandi, Flora, Miri, Syna, Garagiola, Isabella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862552/ https://www.ncbi.nlm.nih.gov/pubmed/33552050 http://dx.doi.org/10.3389/fimmu.2020.591878

Ejemplares similares

Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects
por: De Cristofaro, Raimondo, et al.
Publicado: (2019)

Product type and other environmental risk factors for inhibitor development in severe hemophilia A
por: Peyvandi, Flora, et al.
Publicado: (2018)

The Immune Response to the fVIII Gene Therapy in Preclinical Models
por: Patel, Seema R., et al.
Publicado: (2020)

Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels
por: Trevisan, Brady, et al.
Publicado: (2022)

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
por: Lubich, Christian, et al.
Publicado: (2022)

Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors
por: Bravo, M I, et al.
Publicado: (2014)

Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination
por: Valsecchi, Carla, et al.
Publicado: (2022)

Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination
por: Valsecchi, Carla, et al.
Publicado: (2022)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A
por: Cai, Yuanhua, et al.
Publicado: (2020)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

Development of a Specific Monoclonal Antibody to Detect Male Cells Expressing the RPS4Y1 Protein
por: Spena, Silvia, et al.
Publicado: (2021)

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII
por: Ramamurthy, Ritu M., et al.
Publicado: (2022)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Removal of Mannose-Ending Glycan at Asn(2118) Abrogates FVIII Presentation by Human Monocyte-Derived Dendritic Cells
por: Delignat, Sandrine, et al.
Publicado: (2020)

Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1
por: Matino, Davide, et al.
Publicado: (2020)

Genetic Variants Identified by Whole Exome Sequencing in a Large Italian Family with High Plasma Levels of Factor VIII and Von Willebrand Factor
por: Spena, Silvia, et al.
Publicado: (2023)

FVIII Immunogenicity—Bioinformatic Approaches to Evaluate Inhibitor Risk in Non-severe Hemophilia A
por: Hart, Daniel P.
Publicado: (2020)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Hemophilia A subjects with an intron-22 gene inversion mutation show CD4(+) T-effector responses to multiple epitopes in FVIII
por: Gunasekera, Devi, et al.
Publicado: (2023)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
por: Napolitano, Mariasanta, et al.
Publicado: (2021)

Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies
por: Lacroix-Desmazes, Sébastien, et al.
Publicado: (2021)

Fc Gamma Receptors and Complement Component 3 Facilitate Anti-fVIII Antibody Formation
por: Zerra, Patricia E., et al.
Publicado: (2020)

Complement protein C3a enhances adaptive immune responses towards FVIII products
por: Ringler, Eva, et al.
Publicado: (2023)

Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study
por: Bravo, Maria Isabel, et al.
Publicado: (2022)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Suppression of FVIII-Specific Memory B Cells by Chimeric BAR Receptor-Engineered Natural Regulatory T Cells
por: Pohl, Alessandra De Paula, et al.
Publicado: (2020)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
por: Hemşinlioğlu, Cansu, et al.
Publicado: (2023)

The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay
por: Wada, Hideo, et al.
Publicado: (2021)

Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII
por: Crawford, Bredon, et al.
Publicado: (2015)

B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin
por: Biswas, Moanaro, et al.
Publicado: (2020)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Limited Generalizability of a Retrospective Chart Review Comparing 3 Recombinant FVIII Products for Hemophilia A Prophylaxis
por: Preblick, Ronald, et al.
Publicado: (2020)

Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity
por: Ghaemi, Amir, et al.
Publicado: (2022)

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity
por: Rodriguez, Martin, et al.
Publicado: (2023)

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
por: Leksa, Nina C., et al.
Publicado: (2019)

The Wanderings of Gut-Derived IgA Plasma Cells: Impact on Systemic Immune Responses
por: Keppler, Selina J., et al.
Publicado: (2021)

The IL-10 polarized cytokine pattern in innate and adaptive immunity cells contribute to the development of FVIII inhibitors
por: Silveira, Amanda CO, et al.
Publicado: (2015)

A recurrent F8 mutation (c.6046C>T) causing hemophilia A in 8% of northern Italian patients: evidence for a founder effect
por: Garagiola, Isabella, et al.
Publicado: (2015)

Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A
por: Spena, Silvia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dvk13pmmmblt91s792jq0do6m4